CTMS Provider Velos Joins WCG
Princeton, NJ – January 24, 2019 – The WIRB-Copernicus Group®’s (WCG™) Clinical Services Division has acquired the Velos eResearch business line. Velos is a leading provider of clinical trial management solutions (CTMS) that increase the productivity and efficiency of clinical research. Velos links the administrative, financial, and regulatory elements of clinical research on a single, adaptable, easy-to-use technology platform making the execution of research more organized, more manageable and more profitable for institutions.
“We are pleased to welcome Velos to the WCG family,” said Donald A. Deieso, PhD, Executive Chairman and CEO of WCG. “WCG is privileged to serve more than 2,800 institutions, and we are thrilled to empower them with technology solutions that will increase the efficiency of their research programs.”
WCG partners with 93% of the institutions – and 90% of the academic medical centers – that conduct research in the United States. WCG helps institutions accommodate the changes which are occurring in the rapidly evolving drug development landscape by providing solutions that increase the efficiency and profitability of their research, accelerate patient enrollment and position them to attract increased industry funding.
“Our clients are recognized for their academic and clinical research excellence and scientific achievement,” said John S. McIlwain, MBA, Co-founder and CEO of Velos. “They are a critical part of the clinical research ecosystem. It is our mission to break down the silos and administrative barriers slowing their progress and limiting their growth, to enable them to accelerate breakthroughs in clinical care.”
An Internet platform solution, Velos eResearch simplifies the management of institutional research by linking study status, patient enrollment, calendars, budgets, billing, and electronic data capture (EDC). By centralizing the management of research activities – and the collection of research-related information – on a single electronic platform, Velos increases the efficiency, transparency and accessibility of institutional research.
Like WCG’s previous acquisitions, Velos will operate independently and retain its headquarters in Fremont, CA. WCG will support Velos with access to capital, expertise and corporate operational support.
About WCG (WIRB-Copernicus Group)
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry’s first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protection. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical or LinkedIn.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
